Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure

Heart

Volumn 103, Issue 6, 2017, Pages 414-420

  Ou, Shuo Ming ^a,b   Chen, Hung Ta ^b,c   Kuo, Shu Chen ^a,b,d   Chen, Tzeng Ji ^a   Shih, Chia Jen ^a,b   Chen, Yung Tai ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROPENSITY SCORE; RISK ASSESSMENT; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; FACTUAL DATABASE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; PROTECTION; RISK FACTOR; STROKE; TAIWAN; TIME FACTOR; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CAUSE OF DEATH; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; STROKE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84988457064     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-309687     Document Type: Article

References (30)

1. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000;43:1455-69.
2. McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-51.
3. Center for Drug Evaluation and Research. Guidance industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/downloadsDrugs/GuidanceComplianceRegulatory InformationGuidances/ucm071627.pdf (accessed 1 May 2014).
4. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008;5:73-94.
5. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512.
6. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
7. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-97.
8. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76.
9. McMurray J. The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial. Presented at the Heart Failure Congress 2013, Lissabon, Portugal. 479, 2013;99. abstract.
10. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
11. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-88.
12. Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104:157-63.
13. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
15. Chang HY, Weiner JP, Richards TM, et al. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care 2012;18:721-6.
16. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
18. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
19. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
20. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 2010;21:383-8.
21. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
22. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610.
23. Wang KL, Liu CJ, Chao TF, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 2014;177:86-90.
24. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014;2:573-82.
25. Gitt AK, Bramlage P, Binz C, et al. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting-results of the 1 year follow-up of the prospective DiaRegis registry. Int J Clin Pract 2013;67:1005-14.
26. Fu AZ, Johnston SS, Ghannam A, et al. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes care 2016;39:726-34.
27. Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145-54.
28. Velez M, Peterson EL, Wells K, et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 2015;21:2-8.
29. Fadini GP, Avogaro A, Degli Esposti L, et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J 2015;36:2454-62.
30. Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20.